PTPRCAP

Summary

PTPRCAP (protein tyrosine phosphatase receptor type C associated protein, HGNC:9667) is a protein-coding gene on chromosome 11q13.2, encoding Protein tyrosine phosphatase receptor type C-associated protein (Q14761).

The protein encoded by this gene was identified as a transmembrane phosphoprotein specifically associated with tyrosine phosphatase PTPRC/CD45, a key regulator of T- and B-lymphocyte activation. The interaction with PTPRC may be required for the stable expression of this protein.

Source: NCBI Gene 5790 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 1 total
• Constraint (gnomAD): pLI 0.50 (intermediate), LOEUF 1.49 (unconstrained)
• MANE Select transcript: NM_005608

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:9667
Approved symbol	PTPRCAP
Name	protein tyrosine phosphatase receptor type C associated protein
Location	11q13.2
Locus type	gene with protein product
Status	Approved
Aliases	LPAP, CD45-AP
Ensembl gene	ENSG00000213402
Ensembl biotype	protein_coding
OMIM	601577
Entrez	5790

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 protein_coding

MANE Select: ENST00000326294

Transcript support level (Ensembl TSL; 1 = fully mRNA-supported): TSL 1: 1

ENST00000326294

RefSeq mRNA: 1 — MANE Select: NM_005608 NM_005608

CCDS: CCDS8163

Canonical transcript exons

ENST00000326294 — 2 exons

Exon	Start	End
ENSE00001288436	67435510	67436350
ENSE00001422363	67437617	67437682

Expression profiles

Bgee: expression breadth ubiquitous, 128 present calls, max score 99.43.

FANTOM5 (CAGE): breadth broad, TPM avg 74.5959 / max 3229.1796, expressed in 367 samples.

Highest expression (Bgee): granulocyte, spleen, blood, lymph node, vermiform appendix.

FANTOM5 promoters

4 alternative TSS:

Promoter ID	TPM avg	Samples expressed
120925	73.2190	365
120924	1.3004	132
120922	0.0647	48
120923	0.0118	3

Top tissues by expression

showing 100 of 130 tissues by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
granulocyte	CL:0000094	99.43	gold quality
spleen	UBERON:0002106	98.64	gold quality
blood	UBERON:0000178	97.34	gold quality
lymph node	UBERON:0000029	97.06	gold quality
vermiform appendix	UBERON:0001154	95.86	gold quality
mucosa of transverse colon	UBERON:0004991	93.09	gold quality
small intestine Peyer’s patch	UBERON:0003454	90.66	gold quality
bone marrow cell	CL:0002092	90.13	gold quality
small intestine	UBERON:0002108	88.35	gold quality
bone marrow	UBERON:0002371	87.13	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	84.59	gold quality
right uterine tube	UBERON:0001302	83.73	gold quality
leukocyte	CL:0000738	83.63	gold quality
duodenum	UBERON:0002114	82.88	gold quality
fundus of stomach	UBERON:0001160	82.12	gold quality
monocyte	CL:0000576	82.10	gold quality
upper lobe of left lung	UBERON:0008952	81.81	gold quality
transverse colon	UBERON:0001157	81.30	gold quality
right lobe of liver	UBERON:0001114	80.03	gold quality
body of stomach	UBERON:0001161	80.02	gold quality
right lobe of thyroid gland	UBERON:0001119	79.93	gold quality
left uterine tube	UBERON:0001303	79.15	gold quality
right coronary artery	UBERON:0001625	78.67	gold quality
right lung	UBERON:0002167	78.30	gold quality
intestine	UBERON:0000160	78.29	gold quality
saliva-secreting gland	UBERON:0001044	77.71	gold quality
minor salivary gland	UBERON:0001830	77.51	gold quality
apex of heart	UBERON:0002098	77.51	gold quality
omental fat pad	UBERON:0010414	77.20	gold quality
tonsil	UBERON:0002372	77.10	gold quality
esophagus mucosa	UBERON:0002469	76.97	gold quality
stomach	UBERON:0000945	76.86	gold quality
left lobe of thyroid gland	UBERON:0001120	76.50	gold quality
prostate gland	UBERON:0002367	76.21	gold quality
colon	UBERON:0001155	76.07	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	75.91	gold quality
endocervix	UBERON:0000458	75.52	gold quality
lung	UBERON:0002048	75.48	gold quality
vagina	UBERON:0000996	75.25	gold quality
thyroid gland	UBERON:0002046	74.94	gold quality
cortex of kidney	UBERON:0001225	74.86	gold quality
adipose tissue	UBERON:0001013	74.76	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	74.64	gold quality
ectocervix	UBERON:0012249	74.42	gold quality
liver	UBERON:0002107	74.35	gold quality
esophagus	UBERON:0001043	73.20	gold quality
ascending aorta	UBERON:0001496	72.95	gold quality
thoracic aorta	UBERON:0001515	72.93	gold quality
subcutaneous adipose tissue	UBERON:0002190	72.87	gold quality
myometrium	UBERON:0001296	72.66	gold quality
right ovary	UBERON:0002118	72.53	gold quality
adult mammalian kidney	UBERON:0000082	72.38	gold quality
left coronary artery	UBERON:0001626	72.34	gold quality
mucosa of stomach	UBERON:0001199	72.26	gold quality
thoracic mammary gland	UBERON:0005200	72.26	gold quality
lower esophagus mucosa	UBERON:0035834	72.01	gold quality
body of uterus	UBERON:0009853	71.94	gold quality
metanephros cortex	UBERON:0010533	71.85	gold quality
multicellular organism	UBERON:0000468	71.07	gold quality
descending thoracic aorta	UBERON:0002345	70.92	gold quality
tibial nerve	UBERON:0001323	70.86	gold quality
skin of abdomen	UBERON:0001416	70.80	gold quality
left ovary	UBERON:0002119	70.70	gold quality
lower esophagus	UBERON:0013473	70.37	gold quality
lower esophagus muscularis layer	UBERON:0035833	70.35	gold quality
adenohypophysis	UBERON:0002196	70.31	gold quality
left adrenal gland cortex	UBERON:0035825	69.52	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	69.50	gold quality
substantia nigra	UBERON:0002038	69.49	gold quality
zone of skin	UBERON:0000014	69.46	gold quality
skin of leg	UBERON:0001511	69.40	gold quality
muscle layer of sigmoid colon	UBERON:0035805	69.23	gold quality
right adrenal gland	UBERON:0001233	69.20	gold quality
ovary	UBERON:0000992	69.16	gold quality
right atrium auricular region	UBERON:0006631	68.75	gold quality
putamen	UBERON:0001874	68.61	gold quality
colonic epithelium	UBERON:0000397	68.40	gold quality
right adrenal gland cortex	UBERON:0035827	68.40	gold quality
urinary bladder	UBERON:0001255	68.30	gold quality
pituitary gland	UBERON:0000007	68.27	gold quality
amygdala	UBERON:0001876	68.25	gold quality
temporal lobe	UBERON:0001871	68.21	gold quality
left adrenal gland	UBERON:0001234	67.98	gold quality
uterine cervix	UBERON:0000002	67.72	gold quality
hypothalamus	UBERON:0001898	67.64	gold quality
gall bladder	UBERON:0002110	67.50	gold quality
kidney	UBERON:0002113	67.34	gold quality
fallopian tube	UBERON:0003889	67.16	gold quality
tibial artery	UBERON:0007610	66.99	gold quality
placenta	UBERON:0001987	66.93	gold quality
popliteal artery	UBERON:0002250	66.91	gold quality
Ammon’s horn	UBERON:0001954	66.58	gold quality
heart left ventricle	UBERON:0002084	66.03	gold quality
heart	UBERON:0000948	65.99	gold quality
rectum	UBERON:0001052	65.21	gold quality
body of pancreas	UBERON:0001150	64.98	gold quality
cerebellar cortex	UBERON:0002129	64.62	gold quality
cerebellum	UBERON:0002037	64.61	gold quality
right hemisphere of cerebellum	UBERON:0014890	64.53	gold quality
cerebellar hemisphere	UBERON:0002245	64.50	gold quality

Single-cell (SCXA)

Detected in 29 experiment(s), a significant marker in 22.

Experiment	Marker?	Max mean expression
E-HCAD-15	yes	1113.17
E-MTAB-9801	yes	194.35
E-HCAD-4	yes	139.00
E-HCAD-1	yes	135.41
E-MTAB-6701	yes	112.30
E-MTAB-10553	yes	67.05
E-CURD-122	yes	62.36
E-MTAB-8410	yes	46.10
E-CURD-88	yes	40.82
E-MTAB-6678	yes	38.93
E-HCAD-10	yes	37.61
E-MTAB-10287	yes	35.81
E-GEOD-135922	yes	32.57
E-HCAD-9	yes	28.89
E-MTAB-9067	yes	25.42

HPA expression

RNA tissue specificity: Group enriched

showing 60 of 73 HPA tissues / cells by nTPM:

Tissue / cell	Axis	nTPM	Protein (IHC)
Lymph node	tissue	118.4	high
Thymus	tissue	101.7
Spleen	tissue	89.2	high
Appendix	tissue	68.9	high
Tonsil	tissue	48.1	high
Bone marrow	tissue	25.5	medium
Stomach 1	tissue	23.2	not detected
Small intestine	tissue	18.2	high
Hypothalamus	tissue	14.9
Duodenum	tissue	13.2	high
Periaqueductal gray	tissue	13.0
Spinal cord	tissue	12.6
Substantia nigra	tissue	11.3
Medulla oblongata	tissue	11.1
Lung	tissue	10.1	not detected
Pons	tissue	9.7
Vagina	tissue	9.7	not detected
Salivary gland	tissue	9.6	not detected
Midbrain	tissue	9.4
Septum	tissue	9.0
Colon	tissue	8.7	low
Corpus callosum	tissue	8.6
Superior colliculi	tissue	8.1
Thalamus	tissue	7.2
Pituitary gland	tissue	6.2
Ventral forebrain	tissue	6.0
Urinary bladder	tissue	5.9	not detected
Putamen	tissue	5.8
Amygdala	tissue	5.8
Basal ganglia	tissue	4.9	not detected
Hippocampal formation	tissue	4.9
Cerebral cortex	tissue	3.7	not detected
Temporal cortex	tissue	3.7
Entorhinal cortex	tissue	3.6
Motor cortex	tissue	3.4
Adipose tissue	tissue	3.3	not detected
Olfactory bulb	tissue	3.3
Insular cortex	tissue	3.3
Skin 1	tissue	3.0	not detected
Prefrontal cortex	tissue	3.0
Retrosplenial cortex	tissue	2.9
Gallbladder	tissue	2.8	not detected
Choroid plexus	tissue	2.7
Liver	tissue	2.7	not detected
Prostate	tissue	2.7	not detected
Occipital cortex	tissue	2.7
Adrenal gland	tissue	2.5	not detected
Retrosplenial and cingulate cortex	tissue	2.5
Rectum	tissue	2.2	low
Somatosensory cortex	tissue	2.2
Skeletal muscle	tissue	2.1	not detected
Endometrium 1	tissue	1.7	not detected
Breast	tissue	1.5	not detected
Hippocampus	tissue	1.5	not detected
Locus coeruleus	tissue	1.2
Nucleus accumbens	tissue	1.0
Ovary	tissue	0.9	not detected
Cerebellum	tissue	0.9	not detected
Kidney	tissue	0.9	not detected
Testis	tissue	0.8	low

Brain sub-regions (HPA Brain Atlas): detected in 189; highest nTPM — Dorsal spinal cord (12.6), Ventral spinal cord (11.2), Blood vessel (9.9), White matter (8.6), Dorsal hippocampus (4.9).

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

Targeting PTPRCAP by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific).

9 miRNAs:

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-205-3P	99.92	69.92	3165
HSA-MIR-6842-5P	99.80	67.54	1587
HSA-MIR-7110-5P	99.80	67.84	1712
HSA-MIR-6752-5P	99.59	67.32	1243
HSA-MIR-4649-3P	99.56	66.90	1783
HSA-MIR-6811-3P	98.62	66.54	944
HSA-MIR-4642	97.52	67.60	916
HSA-MIR-656-5P	96.82	67.67	372

Functional genomics

gnomAD constraint: pLI 0.498, LOEUF 1.49, missense Z -1.12 — population loss-of-function intolerance (pLI ≥ 0.9 = LoF-intolerant; lower LOEUF = more constrained). gnomAD

Regional missense constraint (gnomAD RMC): no regional variation along ENST00000326294 — one region, missense o/e 1.03.

Literature-anchored findings (GeneRIF, showing 4)

• We analysed the C77G polymorphism in multiple sclerosis (MS) patients from the genetically homogeneous population of Sardinia. CD45 did not contribute to development of the disease in Sardinian MS. (PMID:15372250)
• Data show that the minor allele of rs869736 in the PTPRCAP promoter is associated with increased susceptibility to diffuse-type gastric cancer by increasing PTPRCAP expression. (PMID:20019842)
• results support the model: following phorbol 12-myristate 13-acetate (PMA) or TCR/CD3 activation of T cells, LPAP is rapidly dephosphorylated at Ser-99 and Ser-172 and slowly phosphorylated at Ser-163. Ser-153 exhibited a high basal level of phosphorylation in both resting and activated cells (PMID:28827793)
• LPAP is a substrate for protein kinase CK2 that phosphorylates it at Ser153, presumably ensuring LPAP resistance to degradation. (PMID:30482149)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Ptprcap	ENSMUSG00000045826
rattus_norvegicus	Ptprcap	ENSRNOG00000021724

Mouse-model phenotypes

Observed phenotypes of the mouse ortholog (MGI:97811) from MGI (Alliance of Genome Resources) — knockout/mutant phenotypes, ranked by annotation count. 5 distinct phenotype terms.

Mouse phenotype (MP)	Records
lymphoid hyperplasia	1
enlarged lymph nodes	1
abnormal cytotoxic T cell physiology	1
decreased B cell proliferation	1
decreased T cell proliferation	1

Genomic neighbors (locus context)

Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).

Symbol	Type	Entrez
TBC1D10C	protein-coding	374403
PPP1CA	protein-coding	5499
CORO1B	protein-coding	57175
CARNS1	protein-coding	57571
RAD9A	protein-coding	5883
RPS6KB2	protein-coding	6199
GPR152	protein-coding	390212
CABP4	protein-coding	57010
TMEM134	protein-coding	80194
MIR6752	ncRNA	102465450
AIP	protein-coding	9049
PITPNM1	protein-coding	9600

Protein

Protein identifiers

Protein tyrosine phosphatase receptor type C-associated protein — Q14761 (reviewed: Q14761)

Alternative names: CD45-associated protein, Lymphocyte phosphatase-associated phosphoprotein

All UniProt accessions (1): Q14761

UniProt curated annotations — full annotation on UniProt →

Subunit / interactions. Interacts with CD45/PTPRC.

Subcellular location. Membrane.

Post-translational modifications. Phosphorylated on tyrosine residues.

RefSeq proteins (1): NP_005599* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR016553	PTPRCAP	Family

Pfam: PF15713

UniProt features (7 total): modified residue 2, chain 1, transmembrane region 1, region of interest 1, compositionally biased region 1, sequence variant 1

Structure

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q14761-F1	58.14	0.08

Human Protein Atlas

Protein class: Predicted intracellular proteins

Protein evidence: Evidence at protein level

Subcellular location (HPA, imaging): plasma membrane

Antibody reliability (HPA): IH enhanced · IF approved

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2)

Type	Positions
Phosphoserine	99, 153

Function

Pathways and Gene Ontology

Reactome pathways

0 curated (TAS) of 0; 0 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).

MSigDB gene sets: 220 (showing top): GSE18804_SPLEEN_MACROPHAGE_VS_COLON_TUMORAL_MACROPHAGE_UP, VERHAAK_AML_WITH_NPM1_MUTATED_DN, MODULE_45, DARWICHE_SKIN_TUMOR_PROMOTER_UP, DARWICHE_PAPILLOMA_RISK_LOW_UP, DARWICHE_PAPILLOMA_RISK_HIGH_UP, DARWICHE_SQUAMOUS_CELL_CARCINOMA_UP, MODULE_16, chr11q13, GGAANCGGAANY_UNKNOWN, BRN2_01, MODULE_171, ZHAN_MULTIPLE_MYELOMA_LB_DN, MODULE_88, WANG_IMMORTALIZED_BY_HOXA9_AND_MEIS1_DN

GO Biological Process (1): defense response (GO:0006952)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (2): plasma membrane (GO:0005886), membrane (GO:0016020)

GO top-level categories

5 GO namespaces:

Category	Terms
response to stress	1
binding	1
membrane	1
cell periphery	1
cellular anatomical structure	1

Experimentally-supported GO annotations

GO terms backed by direct experimental evidence (ECO experimental codes) — 1 of 4 annotations. The rest are phylogenetic / computational / electronic (IEA).

1 experimentally-supported GO terms:

GO term	NS	Evidence
plasma membrane	CC	direct assay

Protein interactions and networks

STRING

showing 15 of 752 interactions by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PTPRCAP	PTPRC	P08575	696
PTPRCAP	CCND1	P24385	487
PTPRCAP	IRAG2	Q12912	398
PTPRCAP	Q92681	Q92681	390
PTPRCAP	N0E472	N0E472	358
PTPRCAP	CSNK2B	P07312	358
PTPRCAP	LY6G5B	Q8NDX9	358
PTPRCAP	SUPV3L1	Q8IYB8	356
PTPRCAP	LCK	P06239	343
PTPRCAP	CNPY4	Q8N129	327
PTPRCAP	GOT1L1	Q8NHS2	327
PTPRCAP	FRMD5	Q7Z6J6	327
PTPRCAP	HS3ST5	Q8IZT8	327
PTPRCAP	LTB	P78370	325
PTPRCAP	ACOT11	Q8WXI4	325

IntAct

Human interaction partners of PTPRCAP in IntAct, one row per partner (best MIscore; records = supporting IntAct interaction records).

4 partners by confidence:

Partner	Interaction type	MIscore	Records
DCDC2	physical association	0.560	3
MYO1C	association	0.350	1
PGRMC1	association	0.350	1
EEF1A1	physical association	0.000	1

BioGRID (16 interactions; top human partners by supporting records): PTPRC (Affinity Capture-Western; 2 records), C1orf27 (Affinity Capture-MS), CMTM6 (Affinity Capture-MS), DCDC2 (Two-hybrid), EEF1A1 (Two-hybrid), FN1 (Affinity Capture-MS), GOSR1 (Affinity Capture-MS), LCK (Affinity Capture-Western), MYO1C (Affinity Capture-MS), OSBPL8 (Affinity Capture-MS), PGRMC1 (Affinity Capture-MS), STX10 (Affinity Capture-MS), STX5 (Affinity Capture-MS), TPM4 (Affinity Capture-MS), UFSP2 (Affinity Capture-MS)

SIGNOR signaling

1 signaling interactions:

A	Effect	B	Mechanism
CSNK2A1	“up-regulates quantity by stabilization”	PTPRCAP	phosphorylation

Protein complexes (CORUM) (1)

Experimentally-characterized complexes this protein is a subunit of (★ = the complex contains a known drug target).

1 complexes by size:

Complex	Subunits	Members
★ CD4 receptor complex	9	PTPRCAP, TFRC, TUBA1C, TUBB, VIM, CD4, LCK, MYH9, PTPRC

Disease & clinical

Genetic variants

Variant evidence for PTPRCAP: 1 ClinVar records (0 pathogenic / likely pathogenic); 2 GWAS associations.

ClinVar

1 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	0
Likely benign	0
Benign	0

SpliceAI

Top 10 splice-impact sites by Δscore (adjacent positions with the same effect merged into one range; 20 predictions of 116):

Position(s)	Effect	Δscore	Sites
11:67436351–67436352	acceptor_loss	0.8800	6
11:67436353	acceptor_loss	0.8700
11:67437615–67437616	donor_loss	0.8600	6
11:67436362	acceptor_loss	0.7600
11:67437614	donor_loss	0.7300
11:67437614	donor_loss	0.6400
11:67437066	donor_gain	0.6300
11:67436350	acceptor_gain	0.6200
11:67437384	donor_gain	0.6000
11:67436356	acceptor_gain	0.5600

AlphaMissense

248 missense substitutions predicted likely pathogenic (of 1,293 scored), across 77 residues. Top 20 hotspot residues, ranked by the number of likely-pathogenic substitutions (of those reachable by a single-nucleotide change), then by mean score:

Residue	Likely-pathogenic substitutions	Mean am_pathogenicity	Max am_pathogenicity
F183	8	0.940	0.991
H181	8	0.712	0.850
W189	7	0.936	0.990
W54	7	0.886	0.980
H66	7	0.799	0.898
S186	6	0.887	0.978
G185	6	0.851	0.943
P67	6	0.828	0.934
D191	6	0.770	0.869
T204	6	0.712	0.929
Y65	5	0.892	0.929
S85	5	0.879	0.952
V203	5	0.774	0.907
W90	5	0.764	0.853
G63	5	0.761	0.849
A187	5	0.748	0.905
L177	5	0.747	0.844
S58	4	0.915	0.953
S178	4	0.851	0.859
A205	4	0.832	0.923

HPA cancer prognostics

RNA cancer specificity: Low cancer specificity

Human Protein Atlas survival analysis — favorable = higher expression predicts better survival.

2 prognostic cancer types:

Cancer	Prognostic	p-value
Head and Neck Squamous Cell Carcinoma (TCGA)	favorable	4.9e-06
Skin Cutaneous Melanoma (TCGA)	favorable	0.000982

Disease associations

OMIM: gene MIM:601577 | disease phenotypes:

GWAS associations

2 associations:

Study	Trait	p-value
GCST010002_193	Refractive error	3e-13
GCST009194_1	Ventral diencephalon volume	6e-6

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4806 (SINGLE PROTEIN)

PharmGKB: 1 entry (CPIC guideline: no)

Binding affinities (BindingDB)

11 measured of 11 human assays (13 total across all organisms); most potent 11 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value
glaucine fumarate	KI	171 nM
5-[3’-(1-adamantyl)-2-chloro-4’-hydroxy-4-biphenyl]-1H-tetrazole	IC50	1200 nM
5-[1-(3’-adamantan-1-yl-2-chloro-4’-hydroxy-biphenyl-4-yl)-meth-(Z)-ylidene]-thiazolidine-2,4-dione	IC50	2300 nM
(S)-1,2-Dimethoxy-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline	IC50	5300 nM
7-Methyl-6,7,7a,8-tetrahydro-5H-benzo[g][1,3]dioxolo[4’,5’:4,5]benzo[1,2,3-de]quinoline	IC50	15000 nM
Phenylsulfanylmethyl-phosphonothioic acid	KI	460000 nM
7-Thiophosphonomethyl-naphthalene-1-carboxylic acid	KI	1.5e+06 nM
6-Thiophosphono-hexanoic acid	KI	1.5e+06 nM
6-Phosphono-hexanoic acid	KI	7e+06 nM
methylphosphonic acid	KI	1.1e+07 nM
Methyl-phosphonothioic acid	KI	1.9e+07 nM

ChEMBL bioactivities

3 potent at pChembl≥5 of 5 total, top 3 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
5.92	IC50	1200	nM	CHEMBL227622
5.64	IC50	2300	nM	CHEMBL376571
5.28	IC50	5300	nM	NORNUCIFERINE

PubChem BioAssay actives

2 with measured affinity, of 26 total; 2 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
2-(1-adamantyl)-4-[2-chloro-4-(2H-tetrazol-5-yl)phenyl]phenol	288593: Inhibition of CD45 PTP by fluorescence spectrometry	ic50	1.2000	uM
(5Z)-5-[[4-[3-(1-adamantyl)-4-hydroxyphenyl]-3-chlorophenyl]methylidene]-1,3-thiazolidine-2,4-dione	288593: Inhibition of CD45 PTP by fluorescence spectrometry	ic50	2.3000	uM

CTD chemical–gene interactions

26 total (human), top 26 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Nickel	increases expression	2
GSK-J4	decreases expression	1
propionaldehyde	decreases expression	1
pentanal	decreases expression	1
jinfukang	affects cotreatment, increases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Aspirin	decreases expression	1
Vehicle Emissions	decreases expression	1
Calcitriol	decreases expression	1
Choline	affects expression	1
Cisplatin	affects cotreatment, increases expression	1
Diethylhexyl Phthalate	increases expression	1
Estradiol	decreases expression	1
Formaldehyde	decreases expression	1
Methyl Methanesulfonate	decreases expression	1
Pantothenic Acid	increases expression	1
Plant Extracts	affects cotreatment, decreases expression	1
Rotenone	decreases expression	1
Tobacco Smoke Pollution	decreases expression	1
Tretinoin	decreases expression	1
Urethane	increases expression	1
Valproic Acid	increases methylation	1
Gold Compounds	increases expression	1
Antirheumatic Agents	decreases expression	1
Okadaic Acid	decreases expression	1
Particulate Matter	decreases expression	1

ChEMBL screening assays

8 unique, capped per target: 8 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL655665	Binding	Compound was tested for inhibition of CD45 tyrosine phosphatase at a concentration of 10 uM in fluorometric assay using DiFMUP	Design and synthesis of phosphotyrosine mimetics. — *Bioorg Med Chem Lett*

Clinical trials (associated diseases)

Via MONDO — disease-level, not drug-specific.

Predicted chemistry — Sugi Predict

The predicted patent-compound landscape for PTPRCAP across ~30M SureChEMBL compounds — explore on Sugi Predict.